Novavax has started a late stage trial of its experimental Covid 19 vaccine in partnership with the UK government ’s Vaccines Taskforce , sending the company ’s shares up 6 % after the bell . 
The trial is expected to enrol and test the vaccine in up to 10,000 participants aged between 18 and 84 years over the next four to six weeks . 
Data from the trial will support regulatory submissions for license in the UK , EU and other countries , the company said . 
The trial will enrol at least 25 % of participants over the age of 65 and prioritise groups most affected by the Covid 19 , the company said . 
